— Company Reports Fourth Quarter 2024 Total Revenues of $62.3 Million, Operating Expenses of $43.0 Million and Year End 2024 Cash Position of $294.2 Million — — Fourth Quarter and Full-Year 2024 Performance Reflects Benefits of Commitment to Strategic Focus, Operational Streamlining, Prudent Cash Management, and Growing Global Momentum of VASCEPA®/VAZKEPA® (icosapent ethyl) Franchise — — Announces 1-For-20 ADS Ratio Change to Maintain Nasdaq Listing — — Company to Host Conference Call Today at 8:00 a.m. EDT — DUBLIN and BRIDGEWATER, N.J., March 12, 2025 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ: AMRN), today announced financial results for the fourth quarter of 2024 and provided a review of fourth quarter and recent operational highlights. “Since taking on the role of CEO of Amarin last year, I have worked with our leadership team and the Board of Directors to identify opportunities to leverage our unique assets, skills and resources to drive value,” said Aaron Berg, President & CEO, Amarin. “In 2024, while still progressing with the early launch in markets outside the U.S. and despite a dynamic generic market in the U.S., we generated more than $200 million in revenue and ended the year with nearly $300 million in cash and no debt — all measures exemplifying the strength and resilience of our franchise and the impact of our disciplined approach to capital deployment. Specifically, we continued to capture efficient branded revenue in the U.S. market for VASCEPA, unlocked access to VASCEPA/VAZKEPA in six additional global markets — including Italy, China and Australia — both on our own and through partnerships, and progressed in an additional 16 countries at various stages towards commercialization. The global VASCEPA franchise remains poised to continue expanding its impact on cardiovascular disease for at-risk patients worldwide.” In addition, Aaron Berg commented, “Building on our efforts and results in 2024, we continue to identify steps to advance the company. As a publicly traded company, there is considerable value in maintaining our Nasdaq listing. To this effect, today we announced our intent to initiate a ratio change to our ADS program.” 1-For-20 ADS Ratio Change In a separate press release issued today, the Company announced its intent to effect a Ratio Change on its American Depositary Shares (“ADS”) from one (1) ADS representing one (1) ordinary share, to the new ratio of one (1) ADS representing twenty (20) ordinary shares (the “Ratio Change”). The effective date of the Ratio Change is expected to be on or about April 11, 2025. The objective of the Ratio Change is to maintain the Company’s listing on the Nasdaq Capital Market and to preserve the Company’s long-term access to the equity capital markets. For further information, please refer to the press release issued on March 12, 2025. Additional questions and answers regarding the Ratio Change can be found under the Investor Relations section of Amarin’s corporate web site here: https://cms.amarincorp.com/sites/default/files/2025-03/e6713d4c-9083-4623-a9e9-6b13d8a4201b.pdf Fourth Quarter 2024 & Recent Operational Highlights The Company continued to advance commercialization and pricing and reimbursement efforts across European markets: In all European countries where VAZKEPA has launched, in-market demand grew in the fourth quarter versus the third quarter of 2024.In Italy, the Company secured national reimbursement. Access has already been unlocked in 9 (of 21) regions of this EU5 market, representing more than 50% of the total VAZKEPA eligible population. Based on recent scientific leader feedback, the appetite for the product is very strong across all regions in Italy.In Austria, national reimbursement for VAZKEPA was secured in late February; as of April 1, 2025, VAZKEPA will be included in Austria’s Code of Reimbursement (EKO). Through partnerships, the Company continues to make progress towards regulatory approvals, access and commercialization in Rest of World (RoW) markets: Two of our partners launched in cardiovascular risk reduction, EddingPharm in China and CSL Seqirus in Australia.While early in the launch phase for a number of RoW markets, all partners saw growth in demand for VASCEPA/VAZKEPA in the fourth quarter.Amarin and its partners are continuing to advance regulatory processes in seven additional RoW markets. The Company’s R&D Team and other investigators have continued to generate, present and publish important new data which add to the significant body of evidence demonstrating the unique benefits of VASCEPA/VAZKEPA. In 2024, a total of 45 additional publications including abstracts, posters, and manuscripts were presented or published that, both individually and in aggregate, helped to advance an ever-broadening understanding of the science and value of icosapent ethyl and EPA. In 2024, investigators presented additional subgroup analyses from the landmark REDUCE-IT® cardiovascular outcomes trial in patients with and without coronary artery disease (CAD) history and data on the mechanistic effects of eicosapentaenoic acid (EPA), including its antioxidant effects in endothelial cells and the ability of EPA to impact the oxidation of Lp(a) particles made of protein and fats (lipids) that carry cholesterol through the bloodstream, at the American Heart Association (AHA) Scientific Sessions. The medical community has increased its focus on Lp(a) as a key cardiovascular risk factor.A recent post hoc analysis of REDUCE-IT published in the Journal of the American Heart Association evaluated the impact of icosapent ethyl on patients with various LDL-C levels at baseline, including those with very well-controlled LDL-C (1% more frequent than placebo): arthralgia (2% vs 1%) and oropharyngeal pain (1% vs 0.3%). Adverse events may be reported by calling 1-855-VASCEPA or the FDA at 1-800-FDA-1088. Patients receiving VASCEPA and concomitant anticoagulants and/or anti-platelet agents should be monitored for bleeding. FULL U.S. FDA-APPROVED VASCEPA PRESCRIBING INFORMATION CAN BE FOUND AT WWW.VASCEPA.COM Europe For further information about the Summary of Product Characteristics (SmPC) for VAZKEPA® in Europe, please visit: https://www.medicines.org.uk/emc/product/12964/smpc. Globally, prescribing information varies; refer to the individual country product label for complete information. Use of Non-GAAP Adjusted Financial Information Included in this press release are non-GAAP adjusted financial information as defined by U.S. Securities and Exchange Commission Regulation G. The GAAP financial measure most directly comparable to each non-GAAP adjusted financial measure used or discussed, and a reconciliation of the differences between each non-GAAP adjusted financial measure and the comparable GAAP financial measure, is included in this press release after the condensed consolidated financial statements. Non-GAAP adjusted net (loss) income was derived by taking GAAP net loss and adjusting it for non-cash stock-based compensation expense, restructuring expense and other one-time expenses. Management uses these non-GAAP adjusted financial measures for internal reporting and forecasting purposes, when publicly providing its business outlook, to evaluate the company’s performance and to evaluate and compensate the company’s executives. The company has provided these non-GAAP financial measures in addition to GAAP financial results because it believes that these non-GAAP adjusted financial measures provide investors with a better understanding of the company’s historical results from its core business operations. While management believes that these non-GAAP adjusted financial measures provide useful supplemental information to investors regarding the underlying performance of the company’s business operations, investors are reminded to consider these non-GAAP measures in addition to, and not as a substitute for, financial performance measures prepared in accordance with GAAP. Non-GAAP measures have limitations in that they do not reflect all of the amounts associated with the company’s results of operations as determined in accordance with GAAP. In addition, it should be noted that these non-GAAP financial measures may be different from non-GAAP measures used by other companies, and management may utilize other measures to illustrate performance in the future. Forward-Looking Statements This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including beliefs about Amarin’s key achievements in 2024 and the potential impact and outlook for achievements in 2025 and beyond; Amarin’s 2025 financial outlook and cash position; Amarin’s overall efforts to expand access and reimbursement to VAZKEPA across global markets; expectations regarding potential strategic collaboration and licensing agreements with third parties, including our ability to attract additional collaborators, as well as our plans and strategies for entering into potential strategic collaboration and licensing agreements and the overall potential and future success of VASCEPA/VAZKEPA and Amarin that are based on the beliefs and assumptions and information currently available to Amarin. All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements regarding Amarin’s planned ratio adjustment and its potential impact on the ADS trading price and on liquidity of the ADSs, as well as Amarin’s ability to regain compliance with Nasdaq’s minimum bid price requirement and other continued listing requirements. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin’s filings with the U.S. Securities and Exchange Commission, including Amarin’s annual report on Form 10-K for the fiscal year ended 2024. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Amarin undertakes no obligation to update or revise the information contained in its forward-looking statements, whether as a result of new information, future events or circumstances or otherwise. Amarin’s forward-looking statements do not reflect the potential impact of significant transactions the company may enter into, such as mergers, acquisitions, dispositions, joint ventures or any material agreements that Amarin may enter into, amend or terminate. Availability of Other Information About Amarin Investors and others should note that Amarin communicates with its investors and the public using the company website (www.amarincorp.com), the investor relations website (www.amarincorp.com/investor-relations), including but not limited to investor presentations and investor FAQs, U.S. Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media, and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Securities and Exchange Act of 1934, as amended. Amarin Contact Information Investor & Media Inquiries: Mark Marmur Amarin Corporation plc PR@amarincorp.com -Tables to Follow- CONSOLIDATED BALANCE SHEET DATA(U.S. GAAP)Unaudited * December 31, 2024 December 31, 2023 (in thousands)ASSETS Current Assets: Cash and cash equivalents$121,038 $199,252 Restricted cash 300 525 Short-term investments 173,182 121,407 Accounts receivable, net 122,279 133,563 Inventory 166,048 258,616 Prepaid and other current assets 12,552 11,618 Total current assets 595,399 724,981 Property, plant and equipment, net 16 114 Long-term inventory 64,740 77,615 Operating lease right-of-use asset 7,592 8,310 Other long-term assets 1,213 1,360 Intangible asset, net 16,389 19,304 TOTAL ASSETS$685,349 $831,684 LIABILITIES AND STOCKHOLDERS’ EQUITY Current Liabilities: Accounts payable$40,366 $52,762 Accrued expenses and other current liabilities 139,583 204,174 Current deferred revenue — 2,341 Total current liabilities 179,949 259,277 Long-Term Liabilities: Long-term deferred revenue — 2,509 Long-term operating lease liability 7,723 8,737 Other long-term liabilities 11,501 9,064 Total liabilities 199,173 279,587 Stockholders’ Equity: Common stock 305,298 302,756 Additional paid-in capital 1,914,750 1,899,456 Treasury stock (65,326) (63,752)Accumulated deficit (1,668,546) (1,586,363)Total stockholders’ equity 486,609 552,097 TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY$685,349 $831,684 * Unaudited as a standalone schedule; copied from consolidated financial statements CONSOLIDATED STATEMENTS OF OPERATIONS DATA(U.S. GAAP)Unaudited * Three Months Ended December 31, Year Ended December 31, (in thousands, except per share amounts) (in thousands, except per share amounts) 2024 2023 2024 2023 Product revenue, net$60,068 $70,555 $204,590 $285,299 Licensing and royalty revenue 2,238 4,158 24,024 21,612 Total revenue, net 62,306 74,713 228,614 306,911 Less: Cost of goods sold 35,399 29,589 110,758 102,142 Less: Cost of goods sold – restructuring inventory 36,474 — 36,474 39,228 Gross margin (9,567) 45,124 81,382 165,541 Operating expenses: Selling, general and administrative (1) 36,970 43,941 152,310 199,938 Research and development (1) 5,985 5,791 20,869 22,219 Restructuring — 229 — 10,972 Total operating expenses 42,955 49,961 173,179 233,129 Operating loss (52,522) (4,837) (91,797) (67,588)Interest income 3,371 3,419 13,403 11,863 Interest expense (3) (2) (7) (8)Other (expense) income, net (753) (1,029) 1,201 2,063 Loss from operations before taxes (49,907) (2,449) (77,200) (53,670)Benefit from (provision for) income taxes 1,289 (3,332) (4,983) (5,442)Net loss$(48,618) $(5,781) $(82,183) $(59,112)Loss per share: Basic$(0.12) $(0.01) $(0.20) $(0.15)Diluted$(0.12) $(0.01) $(0.20) $(0.15)Weighted average shares outstanding: Basic 411,293 408,485 410,937 407,655 Diluted 411,293 408,485 410,937 407,655 * Unaudited as a standalone schedule; copied from consolidated financial statements(1)Excluding non-cash stock-based compensation, selling, general and administrative expenses were $138,144 and $187,445 for the years ended December 31, 2024 and 2023, respectively, and research and development expenses were $17,330 and $18,032, respectively, for the same periods. RECONCILIATION OF NON-GAAP NET (LOSS) INCOMEUnaudited Three months ended December 31, Year Ended December 31, (in thousands, except per share amounts) (in thousands, except per share amounts) 2024 2023 2024 2023 Net (loss) income for EPS – GAAP$(48,618) $(5,781) $(82,183) $(59,112)Stock-based compensation expense 3,400 4,646 17,703 16,680 Restructuring Inventory 36,474 — 36,474 39,228 Restructuring expense — 229 — 10,972 Advisor Fees — — — 6,270 Adjusted net (loss) income for EPS – non-GAAP$(8,744) $(906) $(28,004) $14,038 Basic and diluted (Loss) earnings per share: Basic – non-GAAP$(0.02) $(0.00) $(0.07) $0.03 Diluted – non-GAAP$(0.02) $(0.00) $(0.07) $0.03 Weighted average shares: Basic 411,293 408,485 410,937 407,655 Diluted 411,293 408,485 410,937 422,966
